B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery ( P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence ( P < 0.001 and P = 0.005) and cancer-specific death ( P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, overexpression of B7H3 is associated with disease spread, including increased extracapsular extension and seminal vesicle invasion, as well as worse outcomes, including higher risk of metastatic recurrence or subsequent development of CRPC88.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Self-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citation
Cited by
Items 401–420 of 420
Плотников, Е. В., Оружени, М., Безверхняя, Е. А., Сю, Т., Лю, Ю., Karlberg, I., Орлова, А. М., Максимилианович, Т. В., & Фрейд, Ф. Ю. (2022) · Электронный научный архив ТПУ: Главная страница (Tomsk Polytechnic University)
(2022) · Электронный научный архив ТПУ: Главная страница (Tomsk Polytechnic University)
Mulati, Y., Shen, Q., Chen, Y., Tian, Y., Yao, K., Yu, W., Cui, Y., Shi, X., Pang, X., Chang, D., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-01066-4
Stefanczyk, S. A., Kaiser, X., Hagelstein, I., Lutz, M. S., Holzmayer, S. J., Zekri, L., Märklin, M., & Jung, S. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s533342
Avaliação da imunologia local do adenocarcinoma de próstata primário e metastático
Salustiano, A. C. C. (2025) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2025.tde-25092025-102401
Mécanismes d'immunoévasion dans les leucémies aiguës myéloïdes : la molécules B7-H1
Berthon, C. (2012) · theses.fr (ABES) · doi:10.70675/8241e975zf12cz49dez90d2z28ae11fb4679
Gudavalekar, P. U., Khandave, P. Y., Shalini, S., Selvaraju, S., & Pande, A. H. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104670
Funeh, C. N., Declercq, S., Bridoux, J., Chen, W. M., Sahili, A. E., Lescar, J., D’Huyvetter, M., & Devoogdt, N. (2026) · Research Square · doi:10.21203/rs.3.rs-9664465/v1
Molecular understanding and clinical aspects of adoptive cellular immunotherapy in prostate cancer
Du, X., Yan, Z., Su, P., Liang, H., Dong, D., & Wang, K. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105395
Ye, J., Sun, J., Hou, J., Zhang, L. X., Wu, C., & Xiao, J. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101289
Widdess, M. A., Wilkinson, L., Metcalfe, H. J., Pakidi, A., Chan, H. C., Kim, J., Inzhelevskaya, T., Turaj, A. H., Lim, S. H., Thirdborough, S. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.732642
Schepisi, G., Torresan, I., Giunta, E. F., Bleve, S., Brighi, N., Tassinari, E., Zanuccoli, S., Cursano, M. C., & Lolli, C. (2026) · The Journal of Pathology · doi:10.1002/path.70095
“…resulting in a distinct tumor subtype, characterized by: (1) inhibition of proteasome-mediated degradation with increased PD-L1 expression [171]; (2) increased presence of immunosuppressive lymphocytes within the TME; and (3) marked sensitivity to hormone therapy, even in the case of…”
InfluentialChen, W. M., Kishore, S., Vaibavi, S. R., Yew, W. N., Fradale, L., Bouyx, C., Koh, A., Maricar, S., Pérez, J., Sahili, A. E., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117758
Kwon, J., Lee, S., Kim, J., Yoo, B. M., Park, H. J., Ryu, I., Kim, J., Eom, J., Son, Y.-G., Yeom, D.-H., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2731283
Suresh, S., Maurya, S., Singh, K., Sharma, K., Bar, S., Dagar, A., Uttam, V., Sandeep, S., Ahmad, F., Jain, M., et al. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104814
Lutz, M. S., Zekri, L., Weßling, L., Berchtold, S., Heitmann, J. S., Lauer, U. M., Jung, G., & Salih, H. R. (2023) · doi:10.3389/fimmu.2023.1163136.s001
Hagelstein, I., Engel, M., Hinterleitner, C., Manz, T., Märklin, M., Jung, G., Salih, H. R., & Zekri, L. (2022) · doi:10.3389/fimmu.2022.1002898.s001
Development of prostrate cancer vaccine using PAP as target antigen
Javad, J. M. S. (2014) · Nottingham Trent University's Institutional Repository (Nottingham Trent Repository)
Mascolo, M., Russo, D., & Rosa, G. D. (2013) · Springer eBooks · doi:10.1007/978-94-007-7149-9_1
Metadata
- Authors
- Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Chicago Medical Center (US)
- Pathology, and
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Allison, James P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-12-04
- Volume
- 104
- Issue
- 49
- Pages
- 19458-19463
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2148311
- OpenAlex
- W2164079212
- Cited by
- 401
- References
- 42
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 20 · 2023: 23 · 2022: 27 · 2021: 28 · 2020: 22 · 2019: 19 · 2018: 21 · 2017: 26 · 2016: 31 · 2015: 15 · 2014: 22 · 2013: 25 · 2012: 27
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- National Cancer Institute (T32CA082088)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- B7-H3, prostate cancer, B7/CD28 family, tumor immune evasion, tumor recurrence, cancer-specific mortality, lymph node metastasis, prognostic factors, immunotherapy targets, radical prostatectomy
- MeSH terms
- Humans, Immunohistochemistry, Male, Prognosis, Prostatic Neoplasms, Receptors, Immunologic, Antigens, CD, Survival Analysis, B7-1 Antigen, Disease Progression, B7 Antigens, V-Set Domain-Containing T-Cell Activation Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.